Oroxylin A directly targets transketolase (TKT) to suppress the non‐oxidative pentose phosphate pathway and activate p53 signalling, leading to growth inhibition of hepatocellular carcinoma (HCC) cells, tumours, and patient‐derived tumour organoids. The gene discussed is TP53; the disease is neoplasm.